<?xml version="1.0" encoding="UTF-8"?>
<p>The Gilead SIMPLE trials are a group of two multinational, randomized, open-label trials that examine the efficacy of remdesivir (5- and 10-day dosing) in severe SARS-CoV-2 patients (SIMPLE 1) as well as compare the dosing regimens to SOC among patients with moderate SARS-CoV-2 (SIMPLE 2) [
 <xref rid="REF41" ref-type="bibr">41</xref>-
 <xref rid="REF42" ref-type="bibr">42</xref>]. Published preliminary results from 400 patients enrolled in the SIMPLE 1 trial revealed that there is no significant difference in the time to recovery among patients treated with 5 days versus 10 days of remdesivir [
 <xref rid="REF41" ref-type="bibr">41</xref>]. Despite the similar rates with both treatment durations, it is still unclear if critically-ill patients are more likely to benefit from longer therapy duration due to the lack of mechanically ventilated patients in the study [
 <xref rid="REF41" ref-type="bibr">41</xref>]. The results from the SIMPLE 2 study are not yet available; however, preliminary reports seem promising (press release. SIMPLE 2 trial by Gilead Sciences. June 1, 2020).
</p>
